These findings led us to consider the modulation of SH3BP2 expression as a potential therapeutic approach for SLE, since elevated SH3BP2 protein levels might improve immunological abnormality and organ involvement in SLE. This evidence concerns the gene SH3BP2 and systemic lupus erythematosus.